Kathryn L. O Keefe, 1 Ahmet Kilic, 1 Amy Pope-Harman, 2 Don Hayes, Jr., 2,3 Stephen Kirkby, 2,3 Robert S. D. Higgins, 1 Bryan A. Whitson 1.
|
|
- Marjorie Chase
- 5 years ago
- Views:
Transcription
1 ArtIcle Changes in Pulmonary Artery Pressure Affect Survival Differently in Lung Transplant Recipients Who Have Pulmonary Hypertension or Chronic Obstructive Pulmonary Disease Kathryn L. O Keefe, 1 Ahmet Kilic, 1 Amy Pope-Harman, 2 Don Hayes, Jr., 2,3 Stephen Kirkby, 2,3 Robert S. D. Higgins, 1 Bryan A. Whitson 1 Abstract Objectives: Pulmonary hypertension and right ventricular dysfunction can complicate lung transplant. Pulmonary artery pressures affect outcome are uncertain during wait list. We evaluated changes in wait list pulmonary artery pressures on survival after lung transplant. Materials and Methods: We queried the United Network for Organ Sharing/Standard Transplant Analysis and Research registry from 1987 to 2012 for all lung transplants. Recipients with unique pulmonary artery pressure measurements upon listing and transplant were included. Mean pulmonary artery pressure was rated as increased (increase > 5 mm Hg), decreased (decrease > 5 mm Hg), or unchanged (variation < 5 mm Hg). Results: There were lung transplants and 1677 recipients were included. Diagnoses demonstrated significant changes in mean pulmonary artery pressure during the listing period (P.0001). In recipients with chronic obstructive pulmonary disease, survival was poorer when mean pulmonary artery pressure was increased than decreased (P.03). In recipients with primary pulmonary hypertension, survival was poorer when mean From the 1 Department of Surgery, Division of Cardiac Surgery; 2 Department of Internal Medicine, Division of Pulmonary, Allergy, and Critical Care & Sleep Medicine, Wexner Medical Center, Ohio State University; and the 3 Nationwide Children s Hospital, Department of Pediatrics, Division of Pulmonary Medicine, Columbus, OH, USA Acknowledgements: The authors have no conflicts of interest. There was no external funding for the research. Corresponding author: Bryan A. Whitson, MD, PhD, Division of Cardiac Surgery, Ohio State University, Wexner Medical Center, N-813 Doan Hall, 410 W. 10th Avenue, Columbus, OH USA Phone: Fax: bryan.whitson@osumc.edu Experimental and Clinical Transplantation (2014) 4: pulmonary artery pressure was decreased than increased (P.02). Proportional hazards analysis showed that increases in mean pulmonary artery pressure independently affected survival (hazard ratio, 0.78; 95% confidence interval, ). Conclusions: Although the mechanism is unknown, an increase in mean pulmonary artery pressure in patients with chronic obstructive pulmonary disease is associated with poorer survival after lung transplant. In contrast, patients with primary pulmonary hypertension with decreased mean pulmonary artery pressure have poorer survival after lung transplant. In patients with primary pulmonary hypertension, changes in pulmonary artery pressure may be a surrogate for a failing right ventricular function. In chronic obstructive pulmonary disease, the change in pressure suggests an undetermined progressive process. Further study of right ventricular function is warranted to determine the effects of changes in pulmonary artery pressure on lung transplant recipients. Key words: Hemodynamics, Idiopathic pulmonary fibrosis, Outcomes, Pulmonary failure Introduction Lung transplant is an effective treatment for patients who have various end-stage lung diseases and may improve quality of life and survival in these patients. However, there is a shortage of donor organs, and transplant recipients have a high frequency of early mortality after surgery. There is a need to identify factors that affect primary graft dysfunction and Copyright Başkent University 2014 Printed in Turkey. All Rights Reserved. DOI: /ect
2 284 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: Exp Clin Transplant long-term survival in transplant recipients. Pulmonary hypertension is associated with an increased risk of primary graft dysfunction and death. 1-3 Previous studies that evaluated pulmonary hypertension in recipients have focused primarily on the increase in pulmonary artery pressure (PAP) and the effect of increased PAP on the development of primary graft dysfunction. The purpose of the present study was to assess the effect of changes in waiting list PAP measurements on survival in lung transplant recipients. Materials and Methods We accessed the United Network for Organ Sharing (UNOS)/Standard Transplant Analysis and Research (STAR) Database. 4 This database, maintained by the United States Department of Health & Human Services, contains information about donor characteristics, recipient characteristics before and after transplant, and outcomes from 1987 to the present after solid-organ transplants. Data are entered when a patient is added to the wait list and when the patient undergoes transplant. The data were extracted by individual centers and submitted as aggregate data to the Organ Procurement and Transplantation Network (OPTN), United States Scientific Registry of Transplant Recipients (SRTR), which collates and administers the data. The present study was a retrospective review of the UNOS/STAR registry and was approved by the Institutional Review Board at Ohio State University with a waiver of need for individual consent. We assessed data about all lung transplant recipients who received a lung transplant between 1987 and 2012 in the United States aged 18 years. We limited the analysis to single and bilateral deceased-donor, first-time lung transplant recipients. Patients having revision transplant were excluded. We evaluated PAP measurements when patients were placed on the waiting listed and underwent a lung transplant. Recipients included in the analysis had unique PAP measurements when added to the wait listing and when undergoing a transplant. A change in mean PAP (mpap) was defined as mpap upon being added to the waiting list minus mpap at transplant: mpap change = mpap listing mpap transplant. The mpap was rated as increased (increase > 5 mm Hg), decreased (decrease > 5 mm Hg), or unchanged (variation < 5 mm Hg). Recipients who had no PAP values recorded or had identical measurements at listing and transplant were excluded. Statistical analyses Data were analyzed with statistical software (SAS for Windows version 9.4, SAS Institute Inc., Cary, NC, USA). Results were reported as mean ± standard deviation. Data were analyzed with chi-square test for between-group comparisons. Survival comparisons to evaluate unadjusted all-cause mortality were made with the Kaplan-Meier method. Cox proportional hazards regression model was used to adjust for covariates associated with survival and adjust the survival analysis for potentially confounding patient factors. 5-9 Statistical significance was defined by P.05. Results Study cohort A total of lung transplants were performed between 1987 and 2012 during the study period. There were 1677 recipients who had complete, unique mpap data and satisfied the inclusion criteria according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) flow diagram (Figure 1). 10 Figure 1. Strengthening Reporting of Observational Studies in Epidemiology (STROBE) Flow Diagram of Study Patients Who Were Included and Excluded From the Study Pulmonary artery pressure changes and indications for transplant The most frequent indications for lung transplant were chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) (Table 1). The mpap increased in 555 recipients (33%), decreased in 385 recipients (23%), and was unchanged in 737 recipients (44%) (Table 2). Each diagnosis was
3 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: associated with significant changes in mpap while on the waiting list (Table 2). table 1. Indications for Lung Transplant For Patients in the United Network for Organ Sharing (UNOS) Standard Transplant Analysis and Research (STAR) Database* Indication Entire Included in Database Present Study Chronic obstructive pulmonary disease 7690 (35) 616 (37) Idiopathic pulmonary fibrosis 5596 (26) 464 (28) Primary pulmonary hypertension 795 (4) 109 (7) Cystic fibrosis 2893 (13) 89 (5) Alpha-1 antitrypsin deficiency 1376 (6) 76 (5) Sarcoidosis 646 (3) 64 (4) Revision transplant 0 (0) 0 (0) Other 2889 (13) 259 (15) Total (100) 1677 (100) *Data reported as number (%). table 2. Changes in Mean Pulmonary Artery Pressure From Wait-Listing to Lung Transplant in Study Patients* Mean Pulmonary Artery Pressure Diagnosis Decreased Unchanged Increased Total P Chronic obstructive pulmonary disease 161 (26) 292 (47) 163 (27) Idiopathic pulmonary fibrosis 74 (16) 205 (44) 185 (40) Primary pulmonary hypertension 38 (35) 39 (36) 32 (29) Cystic fibrosis 15 (17) 45 (51) 29 (33) Alpha-1 antitrypsin deficiency 12 (16) 41 (54) 23 (30) Sarcoidosis 14 (22) 21 (33) 29 (45) Other 71 (27) 94 (36) 94 (36) Total (%) 385 (23) 737 (44) 555 (33) 1677 (100) *Data reported as number (%). Pulmonary artery pressure and survival after transplant Kaplan-Meier analysis showed that an increase in mpap was associated with poorer survival in patients who had lung transplant because of COPD. This was significant compared with COPD patients who had a decrease in mpap while on the waiting list (P.03) (Figure 2). When patients who had unchanged mpap were removed from the analysis, significantly lower survival also was demonstrated in COPD patients who had an increase in mpap (P.01) (Figure 2). Patients who had lung transplant because of PPH and who had decreased mpap while on the waiting list had lower survival than patients who had increased mpap (P.02) (Figure 3). When patients who had unchanged mpap were removed from the analysis, there was significantly lower survival in PPH patients who had decreased mpap (P.02) (Figure 3). There were no significant survival differences noted with other diagnoses such as IPF (Figure 4). In multivariate Cox proportional hazards analysis model, several variables independently affected overall survival including increased mpap, recipient race other than white or African-American, African- American donor race, donor age, waiting list time, and recipient age (Table 3). African-American donor race, donor age, waiting list time, and recipient age were factors that had a negative effect Figure 2. Relation Between Changes in Mean Pulmonary Artery Pressure (mpap) From Wait Listing to Surgery and Survival After Lung Transplant in Recipients Who Had Chronic Obstructive Pulmonary Disease P =.0298 P =.0095 (A) Changes in mpap (increased, unchanged, and decreased) had a significant effect on survival. (B) The effect of increases and decreases alone were increased when patients who had unchanged mpap were removed from the analysis. Analysis was by log-rank test with the number at risk over time in the Table below the x axis.
4 286 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: Exp Clin Transplant Figure 3. Relation Between Changes in Mean Pulmonary Artery Pressure (mpap) From Wait Listing to Surgery and Survival After Lung Transplant in Recipients Who Had Primary Pulmonary Hypertension (PPH) P =.0134 P =.014 (A) Changes in mpap (increased, unchanged, and decreased) had a significant effect on survival. (B) The effect of increases and decreases alone were increased when patients who had unchanged mpap were removed from the analysis. Analysis was by log-rank test with the number at risk over time in the Table below the x axis. Figure 4. Relation Between Changes in Mean Pulmonary Artery Pressure (mpap) From Wait Listing to Surgery and Survival After Lung Transplant in Recipients Who Had Idiopathic Pulmonary Fibrosis P =.89 Changes in mpap (increased, unchanged, and decreased) did not affect survival. Analysis was by log-rank test with the number at risk over time in the Table below the x axis. on overall long-term survival of transplant recipients. Increased mpap and recipient race other than white or African-American positively affected overall long-term survival. Diagnosis, recipient sex, donor sex, single- vs bilateral-lung transplant, ischemic time, prostacyclin use, and inhaled nitric oxide use had no effect on overall survival in this model (Table 3). table 3. Proportional Hazards Analysis Associated With Survival After Lung Transplant* Covariate P Hazard Ratio 95% Confidence Interval Mean pulmonary artery pressure Unchanged Decreased NS Increased Diagnosis Sarcoidosis Alpha-1 antitrypsin deficiency NS Cystic fibrosis NS Chronic obstructive pulmonary disease NS Idiopathic pulmonary fibrosis NS Pulmonary hypertension NS Other NS Recipient race White African-American NS Other Recipient sex Male Female NS Donor race White African-American Other NS Donor sex Male Female NS Transplant type Single-lung transplant Bilateral-lung transplant NS Increasing donor age Increasing waiting list time Increasing recipient age Increasing ischemic time NS Prostacyclin use NS Inhaled nitric oxide use NS *N = 1677 patients. NS, not significant (P >.05)
5 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: Statistically significant differences were observed between the waiting list times for patients with increased, decreased, and unchanged mpap (P.01); patients who had increased mpap had the longest mean time on the waiting list (increased mpap, 546 ± 619 d [555 patients]; decreased mpap, 422 ± 467 d [385 patients]; unchanged mpap, 492 ± 619 d [737 patients]). The patient groups differed significantly in mean mpap (increased mpap, 11 ± 5 mm Hg; decreased mpap, -10 ± 5 mm Hg; unchanged mpap, 0 ± 3 mm Hg; P.01). Discussion The present analysis of the UNOS/STAR database showed that changes in waiting list mpap were associated with differences in survival in lung transplant recipients who had COPD or PPH. recipient pulmonary artery pressure and primary graft dysfunction An effort has been made to accurately identify risk factors in either donors or recipients that contribute to primary graft dysfunction. Primary graft dysfunction is the main cause of early morbidity and mortality after lung transplant and correlates with reduced long-term survival. 3 Multiple studies have demonstrated the presence of recipient pulmonary arterial hypertension as a risk factor for developing primary graft dysfunction, increased 90-day mortality, and decreased overall survival. 1,2,10,11 These studies include large registry and multicenter cohort studies. Increases in PAP by 10 mm Hg significantly increase the risk of developing primary graft dysfunction in some cohorts, as reported in a multicenter study of 1255 patients. 10 We used a change in mpap of 5 mm Hg to evaluate survival changes because of several recent studies that evaluated the effect of elevated preoperative mpap on transplant recipient survival and/or the development of primary graft dysfunction. A multicenter cohort study of patients who had IPF showed that an increase in mpap of 8.9 mm Hg was a risk factor for primary graft dysfunction, with an odds ratio of 1.64 for every 10 mm Hg increase in mpap. 13 Another cohort study of patients who had IPF confirmed that increased mpap was a risk factor for increased 90-day mortality after transplant, and mpap 35 mm Hg caused a 1.5-fold increase in early mortality. 12 Changes in relative mortality risk were seen with incremental changes in mpap as low as 5 mm Hg. Therefore, the cutoff of increased mpap 5 mm Hg was justified in the present study because of the previously reported data. effect of pulmonary artery pressure on survival after transplant There are conflicting opinions about whether primary and secondary pulmonary hypertension may be associated with poorer transplant outcomes. 12,13 In a previous study, secondary pulmonary hypertension in patients who had parenchymal lung disease did not preclude successful allograft function, and there was no relation between elevated PAP and poorer longterm survival. 13 Long-term survival after transplant in patients who had COPD was unaffected by the presence or absence of pre-existing, secondary pulmonary hypertension. 14 However, other studies showed that primary and secondary pulmonary hypertension may be associated with decreased survival after transplant. 2,15 The effect of pulmonary hypertension on survival after transplant is well established In recipients who have COPD, elevated mpap has a significant decrease on survival. In 409 recipients who had COPD, pulmonary hypertension was present in 36% COPD recipients, and hypoxemia and hypercapnia affected the mpap. Elevated mpap directly, adversely affected survival in the COPD patients. 14 In the present study, 26% of COPD patients had an increase in mpap, and the increase in mpap negatively affected survival after transplant. Elevation in PAP and depressed right ventricular parameters correlate with poor survival in patients who have IPF. 17 However, the change in mpap in the IPF patients in the present study did not affect survival, possibly because of the small IPF sample size with complete data. Patients who have IPF may have a baseline degree of fibrosis and pulmonary hypertension, and any substantive increase in mpap may precipitate an acute or terminal exacerbation that may necessitate emergency transplant or cause death. Although elevated PAP is associated with poor long-term survival, little information is available about the effect of changing PAP on the development of primary graft dysfunction or recipient survival after transplant. The present data suggest that the presence or absence of pulmonary hypertension
6 288 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: Exp Clin Transplant alone may not affect a patient s outcome. The UNOS database provided an opportunity to evaluate changes in waiting list hemodynamic parameters by evaluating the database entries at wait-listing and transplant. We demonstrated changes in long-term survival based on the analysis of PAP measurements at those 2 times. The present analysis depended on transplant centers measuring and documenting hemodynamic data with separate candidacy and transplant entries in the registry database. The study cohort included a higher percentage of patients who had PPH (109 of 1677 patients [7%]) than the UNOS registry database (795 of patients [4%]), possibly because of the more rigorous measurements of mpap performed at transplant centers in patients with PPH. Patients who had COPD and an elevation in waiting list mpap had a decrease in long-term survival. We postulate that in this group of patients undergoing transplant, an increase in mean PAP may be caused by worsening pulmonary hypertension and/or intrinsic lung disease that may decrease overall survival. In the present study, patients who had PPH and a decrease in waiting list mpap also had significantly decreased long-term survival. Moderate-to-severe right ventricular dysfunction may negatively affect outcomes after lung transplant. 21 It is possible that in the PPH patient population, decreased mpap may be a marker for a failing right ventricle, which may affect survival after transplant. Strengths and limitations For this analysis, we used national data from an administrative database of lung transplant recipients (the UNOS/STAR registry). The study was a retrospective review of the registry data and has limitations inherent with observational studies such as selection and recorder bias. The UNOS/STAR registry contained transplant data only from the United States. The study also was limited by incomplete datasets; many patients from the total transplant registry were excluded because of a lack of unique PAP measurements recorded in the database. There may be the possibility that datasets were inaccurately entered. Although lung transplant for end-stage lung disease is a common procedure, there is a wide range of center volume and practice patterns across the country. Variations between centers in patient care during waiting list time, transplant surgical technique, and postoperative care were not evaluated in this study. Furthermore, there may have been bias in the measurement of mpap at transplant because this measurement may be altered by variations in right ventricular function and volume status. The UNOS/STAR registry and the current listing process may be limited by the absence of an objective measurement of right ventricular function. The PAP and right ventricular function have been correlated using newer electrocardiogram-gated computed tomography and magnetic resonance imaging techniques. 19 These correlations may enable the determination of right ventricular ejection fraction in addition to left ventricular ejection fraction and provide a real-time, noninvasive evaluation of changes in the pulmonary artery system and right ventricular ejection fraction. Determination of right ventricular ejection fraction may enable a more accurate prediction of survival after lung transplant. 19 Despite these limitations, the present study demonstrates significant survival differences in patients undergoing lung transplant. The inclusion and exclusion criteria were precise. The analysis was adjusted to account for potential confounders of the data. We had a large multicenter cohort from the largest registry of transplant patients currently available. The population-based data may reflect the practice and patterns of care across the United States and may be an accurate reflection of the outcomes of these patients. Conclusions The present analysis of the UNOS registry showed that changes in mpap during the waiting list period may affect survival outcomes in patients undergoing lung transplant. In patients who had COPD, an increase in mpap was associated with decreased survival, possibly because of worsening of intrinsic lung disease during the waiting list time. In patients who had PPH, a decrease in mpap caused decreased survival, which may have been caused by the development of right ventricular failure. The present study highlights the importance of obtaining hemodynamic data for lung transplant recipients throughout the time on the waiting list. Further evaluation of changes in waiting list mpap data, and analysis and inclusion of data about recipient
7 Kathryn L. O Keefe et al/experimental and Clinical Transplantation (2014) 4: ventricular function, may clarify the causes of survival differences noted in this study. s 1. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest. 2003;124(4): Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006;131(1): Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007;26(10): Organ Procurement and Transplantation Network. Standard Transplant Analysis and Research Database. U.S. Department of Health & Human Services, Health Resources and Services Administration Web site. about/optndatabase.asp. Accessed January 23, Allen JG, Kilic A, Weiss ES, et al. Should patients 60 years and older undergo bridge to transplantation with continuous-flow left ventricular assist devices? Ann Thorac Surg. 2012;94(6): Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139(3): Kilic A, Merlo CA, Conte JV, Shah AS. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score? J Thorac Cardiovasc Surg. 2012;144(5): Whitson BA, Groth SS, Andrade RS, Habermann EB, Maddaus MA, D'Cunha J. T1/T2 non-small-cell lung cancer treated by lobectomy: does tumor anatomic location matter? J Surg Res. 2012;177(2): Whitson BA, Groth SS, Andrade RS, Maddaus MA, Habermann EB, D'Cunha J. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg. 2011;92(6): Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187(5): Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005;24(9): Barr ML, Kawut SM, Whelan TP, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipientrelated risk factors and markers. J Heart Lung Transplant. 2005;24(10): Huerd SS, Hodges TN, Grover FL, et al. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg. 2000;119(3): Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31(4): Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant. 2009;23(6): Long J, Russo MJ, Muller C, Vigneswaran WT. Surgical treatment of pulmonary hypertension: lung transplantation. Pulm Circ. 2011;1(3): Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest. 2013;144(2): Venuta F, Tonelli AR, Anile M, et al. Pulmonary hypertension is associated with higher mortality in cystic fibrosis patients awaiting lung transplantation. J Cardiovasc Surg (Torino). 2012;53(6): Selimovic N, Andersson B, Bech-Hanssen O, Lomsky M, Riise GC, Rundqvist B. Right ventricular ejection fraction during exercise as a predictor of mortality in patients awaiting lung transplantation: a cohort study. BMJ Open. 2013;3(4). pii: e doi: / bmjopen
We have no disclosures
Pulmonary Artery Pressure Changes Differentially Effect Survival in Lung Transplant Patients with COPD and Pulmonary Hypertension: An Analysis of the UNOS Registry Kathryn L. O Keefe MD, Ahmet Kilic MD,
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationHeart-lung transplantation: adult indications and outcomes
Brief Report Heart-lung transplantation: adult indications and outcomes Yoshiya Toyoda, Yasuhiro Toyoda 2 Temple University, USA; 2 University of Pittsburgh, USA Correspondence to: Yoshiya Toyoda, MD,
More informationShould Orthotopic Heart Transplantation Using Marginal Donors Be Limited to Higher Volume Centers?
ORIGINAL ARTICLES: ADULT CARDIAC ADULT CARDIAC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationBilateral Versus Single Lung Transplant for Idiopathic Pulmonary Fibrosis
ArtIcle Bilateral Versus Single Lung Transplant for Idiopathic Pulmonary Fibrosis Sven Lehmann, 1* Madlen Uhlemann, 2* Sergey Leontyev, 1 Joerg Seeburger, 1 Jens Garbade, 1 Denis R. Merk, 1 Hartmuth B.
More informationGeographic Differences in Event Rates by Model for End-Stage Liver Disease Score
American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant
More informationLung Transplantation in the United States,
American Journal of Transplantation 2009; 9 (Part 2): 942 958 Wiley Periodicals Inc. No claim to original US government works Journal compilation C 2009 The American Society of Transplantation and the
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: heart_lung_transplantation 5/1985 6/2018 6/2019 6/2018 Description of Procedure or Service Combined heart/lung
More informationOutcomes of adults with restrictive cardiomyopathy after heart transplantation
http://www.jhltonline.org Outcomes of adults with restrictive cardiomyopathy after heart transplantation Eugene C. DePasquale, MD, a Khurram Nasir, MD, MPH, b and Daniel L. Jacoby, MD b From the a Division
More informationLung and Lobar Lung Transplant. Populations Interventions Comparators Outcomes Individuals: With end-stage pulmonary disease
Protocol Lung and Lobar Lung Transplant (70307) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/19 Preauthorization Yes Review Dates: 09/09, 09/10, 09/11, 07/12, 03/13, 03/14, 03/15, 03/16,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationSingle-lung transplantation in the setting of aborted bilateral lung transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2011 Single-lung transplantation in the setting of aborted bilateral lung transplantation Varun Puri Tracey Guthrie
More informationExtracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis
Featured Article Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis Massimo Boffini 1, Erika Simonato 1, Davide Ricci 1, Fabrizio Scalini 1, Matteo Marro
More informationOriginal Policy Date
MP 7.03.07 Heart/Lung Transplant Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
More informationMaximizing Donor Lungs: Push and Mend. Amy Pope-Harman, MD. Klassen Research Day. January 22, 2015
Maximizing Donor Lungs: Push and Mend Amy Pope-Harman, MD Klassen Research Day January 22, 2015 Goals Why do we care about donors? Bad things happens to donor lungs Donor criteria history Where we can
More informationMetabolic risk factors are increasingly being recognized
Orthotopic Heart Transplantation in Patients With Metabolic Risk Factors Arman Kilic, MD, John V. Conte, MD, Ashish S. Shah, MD, and David D. Yuh, MD Division of Cardiac Surgery, Department of Surgery,
More informationMedical Policy. MP Heart Transplant. BCBSA Ref. Policy: Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery
Medical Policy MP 7.03.09 BCBSA Ref. Policy: 7.03.09 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 2.01.68 Laboratory Tests for Rejection 2.04.56 Immune Cell Function
More informationDebate: HLA matching matters in children
Annual Congress 2018 14 th to 16 th March, the Brighton Centre, Brighton Debate: HLA matching matters in children Presenting the case for - Dr Jon Jin (JJ) Kim, Nottingham Richard & Ronald Herrick 23 Dec
More informationThe 1-year survival rate approaches 80% for patients
Lung Transplantation for Respiratory Failure Resulting From Systemic Disease Frank A. Pigula, MD, Bartley P. Griffith, MD, Marco A. Zenati, MD, James H. Dauber, MD, Samuel A. Yousem, MD, and Robert J.
More informationMeyer, D; et al. The Future Direction of the Adult Heart Allocation System in the United States. Am J Transplant 2015; Jan 15(1):
January Journal Watch 2015 Burhan Mohamedali, MD Rush University Chicago, Illinois, USA Burhan.mohamedali@gmail.com Rajeev Mohan, MD Scripps Clinic and Green Hospital La Jolla, California, USA Mohan.Rajeev@scrippshealth.org
More informationIMPORTANT REMINDER DESCRIPTION
Medical Policy Manual Transplant, Policy No. 02 Heart Transplant Next Review: March 2019 Last Review: April 2018 Effective: May 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide guidance
More informationHeart/Lung Transplant
Medical Policy Manual Transplant, Policy No. 03 Heart/Lung Transplant Next Review: March 2019 Last Review: April 2018 Effective: June 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide
More informationPressure to expand the donor pool has affected all
Effect of Donor Age and Ischemic Time on Intermediate Survival and Morbidity After Lung Transplantation* Dan M. Meyer, MD; Leah E. Bennett, PhD; Richard J. Novick, MD; and Jeffrey D. Hosenpud, MD Background:
More informationIndications for prolongation of ECMO into the early postoperative period in lung transplantation How we do it
Indications for prolongation of ECMO into the early postoperative period in lung transplantation How we do it W Klepetko, MD Professor of Thoracic Surgery HEAD: DIVISION OF THORACIC SURGERY MEDICAL UNIVERSITY
More informationElevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis
American Journal of Transplantation 2011; 11: 2517 2522 Wiley Periodicals Inc. Brief Communication C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationPulmonary Arterial Hypertension: A Journey to Lung Transplant
PH GRAND ROUNDS Pulmonary Arterial Hypertension: A Journey to Lung Transplant Section Editor Deborah J. Levine, MD Bravein Amalakuhan, MD Pulmonary and Critical Care Medicine Fellow University of Texas
More informationRepeat Organ Transplantation in the United States,
American Journal of Transplantation 2007; 7 (Part 2): 1424 1433 Blackwell Munksgaard No claim to original US government works Journal compilation C 2007 The American Society of Transplantation and the
More informationDOWNLOAD OR READ : LUNG TRANSPLANTATION AN ISSUE OF THORACIC SURGERY CLINICS E BOOK THE CLINICS SURGERY PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : LUNG TRANSPLANTATION AN ISSUE OF THORACIC SURGERY CLINICS E BOOK THE CLINICS SURGERY PDF EBOOK EPUB MOBI Page 1 Page 2 lung transplantation an issue of thoracic surgery clinics e book
More informationLung Transplantation for Primary and Secondary Pulmonary Hypertension
Lung Transplantation for Primary and Secondary Pulmonary Hypertension John V. Conte, MD, Marvin J. Borja, BS, Chandrahas B. Patel, BS, Steven C. Yang, MD, Rajiv M. Jhaveri, MD, and Jonathan B. Orens, MD
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationTHE PRESENCE OR SEVERITY OF SECONDARY PULMONARY HYPERTENSION DOES NOT AFFECT OUTCOMES FOR SINGLE LUNG TRANSPLANTATION ON-LINE SUPPLEMENT
THE PRESENCE OR SEVERITY OF SECONDARY PULMONARY HYPERTENSION DOES NOT AFFECT OUTCOMES FOR SINGLE LUNG TRANSPLANTATION ON-LINE SUPPLEMENT Supplemental Methods: The grading of severity used in the manuscript
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: Original Effective Date: MM.07.024 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 08/01/2014 Section: Transplants Place(s) of Service: Inpatient
More informationGender-Based Analysis of Outcome After Heart Transplantation
article Gender-Based Analysis of Outcome After Heart Transplantation Sandra Eifert, 1 Sieglinde Kofler, 2 Thomas Nickel, 2 Sophia Horster, 3 Amir Khosrow Bigdeli, 1 Andres Beiras-Fernandez, 1 Bruno Meiser,
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationInfluence of Pretransplant Panel-Reactive Antibody on Outcomes in 8,160 Heart Transplant Recipients in Recent Era
CARDIOVASCULAR Influence of Pretransplant Panel-Reactive Antibody on Outcomes in 8,160 Heart Transplant Recipients in Recent Era Lois U. Nwakanma, MD, Jason A. Williams, MD, Eric S. Weiss, MD, Stuart D.
More informationHeart Transplant. Policy Number: Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019
Heart Transplant Policy Number: 7.03.09 Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for a heart transplant
More informationDevelopment of the New Lung Allocation System in the United States
American Journal of Transplantation 2006; 6 (Part 2): 1212 1227 Blackwell Munksgaard No claim to original US government works Journal compilation C 2006 The American Society of Transplantation and the
More informationOverview of paediatric heart-lung transplantation: a global perspective
Editorial Overview of paediatric heart-lung transplantation: a global perspective Yishay Orr The Heart Centre for Children, The Children s Hospital at Westmead, Westmead, NSW 2145, Australia Correspondence
More informationThoracic organ transplantation
American Journal of Transplantation 24; 4 (Suppl. 9): 93 15 Blackwell Munksgaard Blackwell Munksgaard 24 Thoracic organ transplantation Richard N. Pierson III a,, Mark L. Barr b, Keith P. McCullough c,
More informationLung transplantation for high-risk patients with idiopathic pulmonary fibrosis
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2016; 33; 235-241 Mattioli 1885 Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis Nilto
More informationPulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASES AND INTERSTITIAL LUNG DISEASES Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis Stephanie Shin 1, Christopher S. King 2, Nitin
More informationEvolution of Surgical Therapies for End-Stage Cardiopulmonary Failure. Heart Failure at the Shoe XI October 5, 2012
Evolution of Surgical Therapies for End-Stage Cardiopulmonary Failure Heart Failure at the Shoe XI October 5, 2012 Robert S.D. Higgins, MD, MSHA Executive Director, Comprehensive Transplant Center Evolution
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: Original Effective Date: MM.07.024 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 03/23/2012 Section: Transplants Place(s) of Service: Inpatient
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationSurvival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy
Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy Martin S. Maron, MD; Benjamin M. Kalsmith, MD; James E. Udelson, MD; Wenjun Li, PhD; David DeNofrio, MD Background Heart
More informationPulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Eur Respir J 2007; 30: 715 721 DOI: 10.1183/09031936.00107206 CopyrightßERS Journals Ltd 2007 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant A.F. Shorr*, J.L. Wainright
More informationPulmonary Medicine. Shaping the Future of Cystic Fibrosis Care
Pulmonary Medicine Shaping the Future of Cystic Fibrosis Care 2 Nationwide Children s Hospital Pulmonary Medicine In the Section of Pulmonary Medicine at Nationwide Children s Hospital, our innovations
More information5/15/2018. Background. Disclosure Statement
5/15/218 Efficacy of Bronchoscopically-Administered in the Setting of Primary Graft Dysfunction after Lung Transplantation Primary Investigator: Sana Ahmed, PharmD Research Associates: Matthew Soto-Arenall,
More informationJournal Watch. April. REVIEW: Donor-recipient matching in heart transplantation HEART FAILURE AND TRANSPLANTATION
Journal Watch April 2018 Philipp Angleitner, MD Medical University of Vienna Vienna, Austria philipp.angleitner@meduniwien.ac.at Andreas Zuckermann, MD, PhD Medical University of Vienna Vienna, Austria
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationThoracic transplantation
American Journal of Transplantation 23; 3 (Suppl. 4): 91 12 Blackwell Munksgaard 23 Blackwell Munksgaard ISSN 161-2577 Thoracic transplantation Frederick L. Grover a, Mark L. Barr b, Leah B. Edwards c,
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationLUNG ALLOCATION SCORE SYSTEM UPDATE
LUNG ALLOCATION SCORE SYSTEM UPDATE Current Lung Allocation System System was implemented on May 4, 25 The Lung Allocation Score (LAS) is based on a combination of Expected survival in next year without
More informationRegulatory Realities Redefining Benefit of Lung Transplant in the Current Era
Regulatory Realities Redefining Benefit of Lung Transplant in the Current Era Gundeep S Dhillon, MD, MPH Associate Professor of Medicine Medical Director, Lung & Heart-Lung Transplantation Program Stanford
More informationLong-Term Renal Allograft Survival in the United States: A Critical Reappraisal
American Journal of Transplantation 2011; 11: 450 462 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationHeart/Lung Transplant. Description
Subject: Heart/Lung Transplant Page: 1 of 10 Last Review Status/Date: March 2016 Heart/Lung Transplant Description The heart/lung transplantation involves a coordinated triple operative procedure consisting
More informationDoes the Presence of Preoperative Mild or Moderate Coronary Artery Disease Affect the Outcomes of Lung Transplantation?
Does the Presence of Preoperative Mild or Moderate Coronary Artery Disease Affect the Outcomes of Lung Transplantation? Cliff K. Choong, FRACS, Bryan F. Meyers, MD, Tracey J. Guthrie, BSN, Elbert P. Trulock,
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationAssessing the Impact on the Right Ventricle
Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal
More informationUCLA UCLA Electronic Theses and Dissertations
UCLA UCLA Electronic Theses and Dissertations Title The Association Between Left Atrial Volume Index and Liver Transplant Survival Permalink https://escholarship.org/uc/item/40q585jg Author Ershoff, Brent
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLong-term outcomes in heart transplantation using donors with a history of past and present cocaine use
European Journal of Cardio-Thoracic Surgery 47 (2015) e146 e150 doi:10.1093/ejcts/ezu512 Advance Access publication 9 January 2015 ORIGINAL ARTICLE Cite this article as: Jayarajan S, Taghavi S, Komaroff
More informationPolicy #: 374 Latest Review Date: January 2014
Name of Policy: Lung and Lobar Lung Transplant Policy #: 374 Latest Review Date: January 2014 Category: Surgery Policy Grade: C Background/Definitions: As a general rule, benefits are payable under Blue
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: 7.03.07 Last Review: 11/2017 Origination: 11/2001 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationCorporate Medical Policy
Corporate Medical Policy Lung and Lobar Lung Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: lung_and_lobar_lung_transplantation 3/1997 3/2017 3/2018 9/2017 Description
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationFactors associated with 5-year survival in older heart transplant recipients
CARDIOTHORACIC TRANSPLANTATION Factors associated with 5-year survival in older heart transplant recipients Arman Kilic, MD, Eric S. Weiss, MD, MPH, David D. Yuh, MD, Ashish S. Shah, MD, and John V. Conte,
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: Original Effective Date: MM.07.024 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 02/27/2015 Section: Transplants Place(s) of Service: Inpatient
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationHeart/Lung Transplant. Populations Interventions Comparators Outcomes Individuals: With end-stage cardiac and pulmonary disease.
Protocol Heart/Lung Transplant (70308) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/10, 01/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17, 01/18
More informationThe Effect of Ventricular Assist Devices on Post-Transplant Mortality
Journal of the American College of Cardiology Vol. 53, No. 3, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.070
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationArticle. Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes
Article Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes Alexander C. Wiseman* and Jane Gralla Summary Background and objectives Current organ
More informationUpdate on Kidney Allocation
Update on Kidney Allocation 23rd Annual Conference Association for Multicultural Affairs in Transplantation Silas P. Norman, M.D., M.P.H. Associate Professor Division of Nephrology September 23, 2015 Disclosures
More informationSurvival impact of lung transplantation for COPD
Eur Respir J 2010; 36: 74 80 DOI: 10.1183/09031936.00087809 CopyrightßERS 2010 Survival impact of lung transplantation for COPD S. Lahzami*, P.O. Bridevaux #, P.M. Soccal #,", J. Wellinger +, J.H. Robert
More informationDeveloping a Kidney Waiting List Calculator
Developing a Kidney Waiting List Calculator Jon J. Snyder, PhD* Nicholas Salkowski, PhD, Jiannong Liu, PhD, Kenneth Lamb, PhD, Bryn Thompson, MPH, Ajay Israni, MD, MS, and Bertram Kasiske, MD, FACP *Presenter
More informationSurvival Outcomes Following Liver Transplantation (SOFT) Score: A Novel Method to Predict Patient Survival Following Liver Transplantation
American Journal of Transplantation 2008; 8: 2537 2546 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: 7.03.07 Last Review: 11/2018 Origination: 11/2001 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationCorneal transplantation: HLA and age
L Aquila, 24 novembre 2012 Corneal transplantation: HLA and age Federico Genzano Besso*, Paola Magistroni, Piera Santoro*, Silvano Battaglio*, Raffaella Giacometti, Morteza Mansouri and Antonio Amoroso
More informationNHS BLOOD AND TRANSPLANT CARDIOTHORACIC ADVISORY GROUP URGENT HEART ALLOCATION SCHEMES 2015/2016 ACTIVITY SUMMARY
INTRODUCTION NHS BLOOD AND TRANSPLANT CARDIOTHORACIC ADVISORY GROUP URGENT HEART ALLOCATION SCHEMES 2015/2016 ACTIVITY SUMMARY 1 This paper is a review of the usage of the Adult Urgent Heart Allocation
More informationTopic: Lung and Lobar Lung Transplant Date of Origin: March Section: Transplant Last Reviewed Date: March 2013
Medical Policy Manual Topic: Lung and Lobar Lung Transplant Date of Origin: March 2013 Section: Transplant Last Reviewed Date: March 2013 Policy No: 08 Effective Date: September 1, 2013 IMPORTANT REMINDER
More informationAccess and Outcomes Among Minority Transplant Patients, , with a Focus on Determinants of Kidney Graft Survival
American Journal of Transplantation 2010; 10 (Part 2): 1090 1107 Wiley Periodicals Inc. Special Feature No claim to original US government works Journal compilation C 2010 The American Society of Transplantation
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationDisclosures. Afterload on the PV loop. RV Afterload THE PULMONARY VASCULATURE AND ASSESSMENT OF THE RIGHT VENTRICLE
THE PULMONARY VASCULATURE AND ASSESSMENT OF THE RIGHT VENTRICLE Ryan J. Tedford, MD Heart Failure, Mechanical Circulatory Support, and Cardiac Transplantation Division of Cardiology, Department of Medicine
More informationUnder-represented Populations Awaiting OHT. Eileen Hsich, MD Associate Medical Director for the Heart Transplant Assistant Professor of Medicine
Under-represented Populations Awaiting OHT Eileen Hsich, MD Associate Medical Director for the Heart Transplant Assistant Professor of Medicine Disclosures: Supported by NHLBI under Award Number R56HL125420-01A1
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationGastroesophageal Reflux Disease Is Associated With an Increased Rate of Acute Rejection in Lung Transplant Allografts
Gastroesophageal Reflux Disease Is Associated With an Increased Rate of Acute Rejection in Lung Transplant Allografts Kenneth Leeper Jr., Emory University N.S. Shah, Emory University Seth Force, Emory
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationAssociation between idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a meta-analysis
Association between idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a meta-analysis David Bédard Méthot, MD, Internal Medicine Resident Evelyne Leblanc, MD, Internal Medicine Resident
More informationLung and Lobar Lung Transplant
Lung and Lobar Lung Transplant Policy Number: Original Effective Date: MM.07.024 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 09/23/2011 Section: Transplants Place(s) of Service: Inpatient
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More information